Entrada Therapeutics Inc (TRDA) Stock Analysis

Entrada Therapeutics Inc (TRDA) is a publicly traded company in the HEALTHCARE sector. It trades at $6.64, carries a market capitalization of $272.91M. This page summarizes the public market data, fundamentals, and frequently asked questions for TRDA, with GNG Research's proprietary safety, quality, and valuation analysis available to members.

Sector: HEALTHCARE - BIOTECHNOLOGY

Exchange: NASDAQ

Key Metrics

• Price: $6.64
• Market Cap: $272.91M
• EPS: $-4.00
• 52-Week High: $16.45
• 52-Week Low: $4.93

Market Sentiment

Entrada Therapeutics Inc currently has a Neutral sentiment score of 0.08.

About Entrada Therapeutics Inc

None

GNG Research Analysis

GNG Research scores Entrada Therapeutics Inc (TRDA) on three proprietary dimensions — a Safety score, a Quality score, and a Valuation score — alongside fair value estimates and buy-price targets for 5,000+ companies. These ratings are reserved for members. Read how the scores are calculated on our methodology page, or see GNG Research plans to unlock the full rating for TRDA.

Frequently Asked Questions

Does TRDA pay dividends?

Entrada Therapeutics Inc (TRDA) does not currently pay a regular dividend.

What is TRDA's market cap?

Entrada Therapeutics Inc (TRDA) has a market capitalization of $272.91M with a current stock price of $6.64.